Breast Biopsy Market Size, Share, Statistics, Trend Analysis and Forecast Report, 2021 - 2028

Breast Biopsy Market is segmented by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)), and Geography.

  • Report ID : MD2793
  • |
  • Pages : 220
  • |
  • Tables : 70
  • |
  • Formats :

The Breast Biopsy market is expected to reach USD 1.169 billion by 2028 from USD 725 million in 2020 at 8.6% CAGR.

Breast Biopsy is a simple, non-invasive procedure where a small sample portion of the breast tissue is extracted and sent for laboratory testing. This is commonly done when suspicious lumps or cancerous portion in breast is present.

The popularity of minimally invasive procedures along with image-guided needle biopsies like vacuum assisted biopsy and core needle biopsy as well as new product approvals are the main attributes that drive this market to a significant growth.

Since breast cancer is one of the most common and prevalent diseases among women in developing or developed countries, it is still the second leading cause of cancer related deaths globally.

As per the American Cancer Society and the National Cancer Institute, there are over 265, 000 new cases recorded with regard to invasive breast cancer diagnosed among women in the US and 63, 960 non-invasive new cases. With the increasing percentage of women having breast cancer, governments around the world are raising awareness in the promotion of its early detection. This of course majorly contributed to the market growth.

Attractive Opportunities in the Breast Biopsy Market

The growth of this market can also be attributed to the rising cases of breast cancers as well as awareness of early breast cancer detection.

The emergence of liquid biopsy and clinical trials showing potential assists physicians in detecting early signs of cancer. This technique is better than the traditional needle biopsy and can identify cancer in its early stages.

Restraint: Risk of Infections

Core needle and fine needle under biopsy needle procedures help radiologists and surgeon in determining abnormalities in a particular area. But the disadvantage of such is that patients can suffer from infections contracted during these procedures because it involves cuts and incisions when removing tissue sample. Consequently, the exposed surface area of the skin where the sample was taken can be prone to bacterial infections and in several unfortunate cases, biopsy needles are being re-used.

This practice has been frowned upon by healthcare authorities, but most professionals and end users still do this especially in developing countries.

Key Findings in the Breast Biopsy Market

By product segment, biopsy needles has the largest share accounted for in the breast biopsy market. This is owing to the rise in adopting image guided procedures whether in developed or developing countries and the introduction of advanced technological equipment and original new designs.

The advancement in needle biopsy includes the tri-axial needle which allows professionals to cut through tissues without traumatizing it since it is more effective because of its pincer needles. Continuous advancement in terms of design allows good visibility of needle under ultrasound and CT which is needed for guidance in biopsy.

In terms of type, liquid biopsy dominates as being a technique so revolutionary. Growth of this segment is due to adoption of novel NGS-based assays and droplet digital PCR technology.

Asia Pacific dominates the market

APAC has the highest growth for breast biopsy market especially considering the emerging economies of countries such as China, India and South Korea. These countries are leading in terms of major investments in advanced systems along with liquid breast biopsy also vacuum-assisted biopsy instruments. The other major factors driving the growth of market in this region are: rising awareness on early detection of breast cancer, rising number of awareness programs, increased number in cases, and the high prioritization of governments with regard to funding cancer research studies and clinical trials.

Key Players: Share and Competition

The leading companies driving the growth of the market and promoting it are, Hologic, Inc. (US), Danaher Corporation (US), and Becton, Dickinson and Company (US), QIAGEN (Netherlands), and Illumina, Inc. (US). there are other key players too aside from the top five leading companies mentioned previously. These are, Merit Medical Systems (US), Medtronic (Ireland), IZI Medical Products (US), Argon Medical (US), STERYLAB S.r.l. (Italy), Scion Medical Technologies, LLC (China), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), and Thermo Fisher Scientific, Inc. (US).

Hologic, Inc. dominates as it has a very competitive product portfolio with an insight-driven innovation that caused its massive expansion in the market. This company also launched Brevera Breast Biopsy System with CorLumina Imaging technology in the US and Europe. It is expected that Hologic, Inc. Will sustain its market growth during the forecast period.

Report Highlights
• Historical data available (as per request)
• Estimation/projections/forecast for revenue and unit sales (2021 – 2028)
• Data breakdown for every market segment (2021 – 2028)
• Gross margin and profitability analysis of companies
• Price analysis of each product type
• Business trend and expansion analysis
• Import and export analysis
• Competition analysis/market share
• Supply chain analysis
• Client list and case studies
• Market entry strategy

Industry Segmentation and Revenue Breakdown

Product Analysis (Revenue, USD Million, 2021 - 2028)

• Biopsy Needles
• Guidance Systems
• Biopsy Tables
• Localization Wires
• Assay Kits
• Liquid Biopsy Instruments
• Others

Type Analysis (Revenue, USD Million, 2021 - 2028)

• Needle Breast Biopsy
• Core Needle Biopsy (CNB)
• Fine Needle Aspiration Biopsy (FNAB)
• Vacuum-assisted Biopsy (VAB)
• Open Surgical Breast Biopsy
• Excisional
• Incisional
• Liquid Breast Biopsy
• Circulating Tumor Cells
• Circulating Tumor DNA (CtDNA)
• Other Biomarkers

Guidance Analysis (Revenue, USD Million, 2021 - 2028)

• Image-Guided Biopsy
• Mammography-guided Stereotactic Biopsy
• Ultrasound-guided Biopsy
• MRI-guided Biopsy
• Other Guidance Techniques
• Liquid Biopsy
• NGS-based Biopsy
• PCR-based Biopsy
• Microarray-based Biopsy

Application Analysis (Revenue, USD Million, 2021 - 2028)

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

Region Analysis (Revenue, USD Million, 2020 – 2028)

• United States
• Canada
• Mexico
• France
• Germany
• Italy
• Spain
• United Kingdom
• Russia
• China
• India
• Philippines
• Malaysia
• Australia
• Austria
• South Korea
• UAE
• Qatar
• Saudi Arabia
• Japan
• Africa
• Rest of World

Available Versions:
• United States Breast Biopsy Industry Research Report
• Europe Breast Biopsy Industry Research Report
• Asia Pacific Breast Biopsy Industry Research Report

PURCHASE OPTIONS

20% Free Customization ON ALL PURCHASE

*Terms & Conditions Apply

Request Free Sample

Please fill in the form below to Request for free Sample Report

  • Office Hours Mon - Sat   10:00 - 16:00

  • Send Us Mail sales@marketdecipher.com